Abstract:Background and purpose:Progesterone receptor(PR) status provides predictive value for adjuvant endocrine therapy in estrogen receptor(ER)-positive breast cancer patients.It is recommended for the patients with both ER and PR positive to receive adjuvant hormone therapy.However,it still is a controversial issue how much efficacy of adjuvant endocrine therapy is for ER(-)PR(+) tumors.This study was to investigate the options of adjuvant endocrine therapy for ER(+)PR(+) primary breast cancer(205 cases) and ER(-)PR(+) primary breast cancer(798 cases).Methods:The expressions of ER and PR status in 1836 consecutive operable patients of primary breast cancer were treated into Shanghai Cancer Hospital between Jan 1991 and Dec 2001 and reviewed.The differences of DFS and OS for ER(-)PR(+) group and ER(+)PR(+) group with or without endocrine therapy were analyzed with median following period up to 48 months(6-141 months).The survival time were calculated by Kaplan-Meier and 5-year survival rates were evaluated by Life Table estimates.Results:ER(-)PR(+) patients accounted for 11.0% of the whole population,and median age was 49 years.The proportion of premenopausal patients was higher in ER(-)PR(+) group(63.9%) compared to ER(+)PR(+) group,the ER(-)PR(+) group had also more auxiliary lymph node metastases,larger mass and higher clinical staging than that in ER(+)PR(+) group.The DFS and OS were similar between both groups in the absence of endocrine therapy,however,the ER(+)PR(+) group had a significant better survival than ER(-)PR(+) group if hormonal treatment was added into the treatment(DFS:P=0.016,OS:P=0.007),and both groups had better 5-year survival after the treatment of hormonal therapy.The 5-year DFS rate increased from 68.7% to 79.0% in ER(+)PR(+) group,and from 56.6% to 70.9% in ER(-)PR(+) group;similar results were found in OS.The multivariate analysis showed that the status of auxiliary lymph node metastases was only important independent prognostic factor for ER(-)PR(+) patients.Conclusions:The adjuvant endocrine therapy is more effective for ER(+)PR(+) primary breast cancer than for ER(-)PR(+) primary breast cancer.Further study is needed determined the best option of hormone therapy for the patients with ER(-)PR(+) status.

Efficacy and safety of traditional Chinese medicine in managing bone loss post-endocrine therapy in hormone receptor-positive breast cancer patients

EFFECT OF ADJUVANT ENDOCRINE THERAPY ON ESTROGEN RECEPTOR-NEGATIVE, PROGESTERONE RECEPTOR-POSITIVE AND HER2 NEGATIVE BREAST CANCER PATIENTS

Chinese medicinal herbs for reducing endocrine therapy-induced side effects in patients with hormone receptor-positive breast cancer: a systematic review and meta-analysis

Strategies and Progress of Endocrine Therapy for Patients with Metastatic Breast Cancer.

Long-term endocrine therapy-related adverse drug reactions in patients after breast cancer surgery and treatment strategies

The recent progress of endocrine therapy-induced osteoporosis in estrogen-positive breast cancer therapy

Progresses in adjuvant endocrine treatment of pre -menopausal patients with breast cancer

A nation-wide multicenter 10-year (1999-2008) retrospective clinical study of endocrine therapy for Chinese females with breast cancer

Adherence to endocrine therapy among Chinese patients with breast cancer: current status and recommendations for improvement.

Endocrine Therapy As Adjuvant or Neoadjuvant Therapy for Breast Cancer: Selecting the Best Agents, the Timing and Duration of Treatment

Endocrine Treatment-Related Symptoms And Outcomes In Breast Cancer: A Systematic Review And Meta-Analysis.

Advances in Endocrine and Targeted Therapy for Hormone-Receptor-positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer

The Efficacy of Adjuvant Endocrine Therapy for ER(-)PR(+) Primary Breast Cancer

Neoadjuvant chemotherapy combined with endocrine therapy for hormone receptor-positive breast cancer: A systematic review and meta-analysis

Efficacy and clinical outcome of chemotherapy and endocrine therapy as first-line treatment in patients with hormone receptor-positive HER2-negative metastatic breast cancer

Efficacy and Safety of Initial 5 Years of Adjuvant Endocrine Therapy in Postmenopausal Hormone Receptor-Positive Breast Cancer: A Systematic Review and Network Meta-Analysis

Endocrine consequences of breast cancer therapy and survivorship

Adjuvant endocrine monotherapy for postmenopausal early breast cancer patients with hormone-receptor positive: a systemic review and network meta-analysis

The therapeutic effect of traditional Chinese medicine on breast cancer through modulation of the Wnt/β-catenin signaling pathway

Cancer Treatment-Induced Bone Loss (CTIBL): State of the Art and Proper Management in Breast Cancer Patients on Endocrine Therapy

What is the optimal endocrine therapy for postmenopausal women with hormone receptor-positive early breast cancer?